NCT01885156已完成3 期
A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 65
- 试验地点
- 5
- 主要终点
- Safety of Naftin® 1% Cream, applied once daily for 4 weeks, compared to vehicle for treatment of subjects with KOH positive symptomatic tinea cruris in adolescent subjects (aged 12 years to 17 years, 11 months).
研究概览
简要总结
To see how well Naftin 1% cream works when applied once daily to the affected area. The results will be compared to those using a placebo cream, which is a cream with no active ingredient. Safety will also be measured.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 12 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Review and sign statement of Informed Consent and HIPAA authorization.
- •Males or non-pregnant females ≥ 12 years of age to 17 years, 11 months, of any race or sex. Females of child-bearing potential must have a negative urine pregnancy test.
- •The parent/legal guardian must complete the informed consent process AND the subject must complete the assent process and sign the appropriate form (if age appropriate).
- •Presence of tinea cruris characterized by clinical evidence of a tinea infection (at least moderate erythema, moderate scaling, and mild pruritus) based on signs and symptoms.
- •KOH positive baseline skin scrapings obtained from the site most severely affected or a representative site of the overall severity.
- •Subjects must be in good health and free from any clinically significant disease that might interfere with the study evaluations.
- •Subject must be able to understand the requirements of the study and willing to comply with the study requirements.
排除标准
- •A life threatening condition (ex. autoimmune deficiency syndrome, cancer, unstable angina, or myocardial infarction) within the last 6 months.
- •Subjects with abnormal findings - physical or laboratory - that are considered by the investigator to be clinically important and indicative of conditions that might complicate interpretation of study results.- Severe dermatophytoses, mucocutaneous candidiasis, or bacterial skin infection.
- •Subjects with a known hypersensitivity to study medications or their components.
- •Subjects who have a recent history or who are currently known to abuse alcohol or drugs.
- •Uncontrolled diabetes mellitus.
- •Hemodialysis or chronic ambulatory peritoneal dialysis therapy.
- •Current diagnosis of immunocompromising conditions.
- •Atopic or contact dermatitis.
- •Severe dermatophytoses, mucocutaneous candidiasis, or bacterial skin infection.
- •Female subject who is pregnant or lactating, who is not using or does not agree to use an acceptable form of contraception during the study, or who intends to become pregnant during the study (females who are surgically sterilized for at least 2 years are not considered to be of childbearing potential).
- •Subjects using the following medications:
- •Topical anti-fungal therapy, powders or topical corticosteroids applied within 14 days prior to randomization. Terbinafine, butenafine, and naftifine (topical) within 30 days prior to randomization.
- •Oral anti-fungal therapies within 3 months of randomization (8 months for oral terbinafine).
- •Systemic antibiotic or corticosteroid treatment within 30 days of randomization.
- •Any other significant treatments, except hormonal contraception and multivitamin, at the discretion of the investigator that would interfere with study treatment.
研究组 & 干预措施
Placebo Cream
Placebo Comparator
Topically applied once daily
干预措施: Placebo Cream (Drug)
Naftin 1% Cream
Experimental
Topically applied once daily
干预措施: Naftin 1% Cream (Drug)
结局指标
主要结局
Safety of Naftin® 1% Cream, applied once daily for 4 weeks, compared to vehicle for treatment of subjects with KOH positive symptomatic tinea cruris in adolescent subjects (aged 12 years to 17 years, 11 months).
时间窗: Week 6
- Summarization of AEs (local and systemic)
次要结局
- Efficacy of Naftin® 1% Cream, applied once daily for 4 weeks, compared to vehicle for treatment of subjects with KOH and culture positive symptomatic tinea cruris in adolescent subjects (aged 12 years to 17 years, 11 months).(Week 6)
研究者
研究点 (5)
Loading locations...
相似试验
已完成
4 期
Pediatric Subjects With Tinea CorporisTinea CorporisNCT02227290Merz North America, Inc.230
已完成
3 期
Safety and Efficacy of IDP-118 in the Treatment of Plaque PsoriasisPlaque PsoriasisNCT02462070Bausch Health Americas, Inc.203
已完成
3 期
Efficacy and Safety of NAFT-600 in Subjects With Tinea PedisTinea PedisNCT01289015Merz North America, Inc.855
已完成
1 期
A Phase 1 Trial of OPA-15406 Ointment in Healthy Adult Male SubjectsAtopic DermatitisNCT02334787Otsuka Pharmaceutical Co., Ltd.32
招募中
3 期
Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune ThrombocytopeniaChronic Primary Immune Thrombocytopenia (ITP)NCT06004856Beijing InnoCare Pharma Tech Co., Ltd.195